Rituximab ITP Aiha denied as experimental or investigational by Humana?

Humana's specific coverage criteria for rituximab itp aiha are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Rituximab (ITP/AIHA) as Experimental

Humana's clinical coverage policies designate certain uses of rituximab as "experimental, investigational, or unproven" when the submitted diagnosis does not match the indications Humana has determined to be established based on its own evidence review. For ITP and AIHA, rituximab is used off-label (its FDA approval is for different conditions), but it has substantial published medical literature behind it and is recognized by leading hematology societies. Humana's own policy language and the date of its last evidence review are central to whether this denial holds up.

## Why This Denial Is Appealable

A use does not have to be FDA-approved to be covered. Under ERISA and the ACA, plans that exclude "experimental" treatments must define that term consistent with accepted medical standards. If rituximab for ITP or AIHA is recognized in authoritative medical compendia or by the relevant specialty society (consult your hematologist regarding current guideline recognition), Humana's "experimental" classification is open to challenge. Your prescriber should address this directly in the appeal letter.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline on the denial notice. Under ERISA §503 and ACA §2719, Humana must provide a full-and-fair review and issue a written decision with specific reasons.
• External review: Federal rules generally allow approximately four months from the internal denial to request IRO review. This is particularly important for "experimental" denials — an independent clinician reviewer will assess whether the use meets accepted medical standards, independent of Humana's internal policy.
• Expedited review: Request immediately if the patient has active significant bleeding (ITP) or symptomatic severe anemia (AIHA).

## Documentation to Gather

• Hematologist letter: Should address why rituximab is the appropriate choice for this patient's specific clinical situation, referencing the recognized body of medical evidence and the relevant hematology society guidelines (without citing specific numbers).
• Clinical severity documentation: CBC results, transfusion history, bleeding events, hemolysis markers, and functional status notes establishing that this is not a mild or easily managed case.
• Prior-treatment failure record: Dated documentation of all prior therapies trialed, with outcomes — demonstrating that standard first- and second-line options have been attempted.
• Humana's experimental-use policy: Obtain the current version and note the date of Humana's evidence review — if it is out of date, that is an appeal argument.

## Criteria-Mapping Structure

In a two-column table, list each criterion in Humana's experimental-use or coverage policy on the left, and the supporting chart evidence or prescriber statement on the right. Include a separate row addressing the "experimental" classification directly, with the prescriber's written opinion that the use meets accepted medical standards.